OHIO OPTICAL DISPENSERS BOARD RECOGNITION FOR THOMAS STEINEMANN, MD
The members and staff of the Ohio Optical Dispensers Board recognized CLAO Board Member Thomas L. Steinemann, MD via a "Memorandum of Appreciation" for promoting eye health and safety. The following quote is from this Memorandum: "The Board recognizes and commends you for your participation and accomplishments to encourage Congress to amend federal law in 2005 to mandate that all contact lenses, including cosmetic or colored contacts, are restricted medical devices requiring a prescription from a medical professional for purchase." The Memorandum additionally recognizes Dr. Steinemann for his support "of the Board's efforts in the areas of monitoring and stopping illegal dispensing and sales of contact lenses in Ohio."
IN MEMORIAM: JOSEPH COLIN, MD
Dr. Joseph Colin, passed away Saturday, February 23, 2013, he was 63 years of age. He is survived by his wife Florence Malet-Colin, MD and children Mélanie, Tiphaine and Timothée.
Dr. Colin was the chairman of the Department of Ophthalmology at Bordeaux University Medical School and served on the boards of the French Society of Refractive Surgery and the French Eye Bank. In addition, he served on the editorial boards of Ocular Surgery News Europe Edition, Journal of Refractive Surgery, Journal of Cataract and Refractive Surgery, European Journal of Ophthalmology and Journal Français d'Ophtalmologie. Dr Colin was also a member of ASCRS' Refractive Surgery Clinical Committee. He will be missed by all who knew him and his legacy will live on through the many patients and colleagues whose lives he touched.
CLAO SYMPOSIUM AT THE ASCRS ANNUAL MEETING
CLAO will be holding its annual symposium at the 2013 ASCRS Symposium and Congress. The symposium will be held in Room 132-133 at the Moscone Convention Center in San Francisco, California, on Monday, April 22, 2013 from 1:00 - 2:30 pm. The symposium is entitled "Problems Post-Op: Pain and Inflammation in the Refractive Surgery Patient," Incorporating the 2013 Richard L. Lindstrom, MD, Lecture." The moderators are Deborah S. Jacobs, MD, Deepinder K. Dhaliwal, MD, L.Ac., Warren R. Fagadau, MD, and Harold A. Stein, MD. This symposium will cover the latest developments in the screening, prevention, and treatment of pain and of inflammation after surface ablation and LASIK. One of the highlights of this symposium will be the delivery of the 2013 Richard L. Lindstrom MD Lecture by Steven E. Wilson, MD. The title of Dr. Wilson's presentation will be "LASIK, Dry Eye, and Complex Regional Pain Syndrome: What All Surgeons Need to Know." The ASCRS Meeting Number for this symposium is S-16.
AAO YEAR IN REVIEW
The American Academy of Ophthalmology provides cutting-edge clinical education and hosts one of the world's biggest ophthalmology meetings. It is ultimately through the collective support of its 32,000 member ophthalmologists that the Academy is able to better serve the profession and the public. View the 2012 Year in Review for an overview of the Academy's many strategic initiatives on behalf of its members and the patients they serve.
Alcon Vision Care announced on January 21st the "launch of ILEVRO™Suspension, a new once-daily treatment option for pain and inflammation associated with cataract surgery. In two double masked, randomized clinical trials, ILEVRO™ Suspension demonstrated superior clinical efficacy compared to its vehicle. In the studies, patients treated with ILEVRO™Suspension were less likely to have ocular pain and measurable signs of inflammation (cells and flare) at the end of treatment than those treated with its vehicle. Patients administered ILEVRO™Suspension experienced superior outcomes when compared to those on vehicle in the following areas:"
Inflammation resolved at day 14 in 65 percent of ILEVRO™Suspension patients vs. 32 percent of patients on vehicle
Pain resolution rates in ILEVRO™Suspension treated patients were 86 percent compared to 46 percent of patients on vehicle
"The most frequently reported ocular adverse reactions following cataract surgery were capsular opacity, decreased visual acuity, foreign body sensation, increased intraocular pressure, and sticky sensation. These reactions occurred in approximately 5 to 10% of patients. For more information on ILEVRO™Suspension visit alcon.com and refer to accompanying full prescribing information."
In other news, the company announced that Dwight Akerman, OD, has been appointed Head, Global Professional Affairs for Alcon's Global Vision Care Franchise. Dr. Akerman will report to Eric Bruno, Global Franchise Head, Vision Care. In his new role, Akerman will be responsible for creating the vision, strategy and roadmap for Professional Affairs globally. He will also provide thought leadership, scientific and technical guidance, and be the voice/mindset of eyecare professionals to the Global Vision Care Franchise to ensure that their products and services better meet the changing demands of the eyecare marketplace. Akerman has served as the head of Professional Affairs & Clinical Research for Wesley Jessen Corporation, Global Head of Medical Marketing for Novartis Pharmaceuticals Ophthalmic Business Unit, Director of Professional Affairs, Americas Region for CIBA Vision, and most recently, Director of Professional Affairs for U.S. Vision Care.
Bausch and Lomb, Inc., has named Robert Bertolini as President and Chief Financial Officer effective immediately. In this capacity, he will oversee the company's Finance, Information Technology and Global Quality and Operations (GQO) functions. Bertolini, who assumes CFO responsibilities from Brian J. Harris, will report to B+L's Chief Executive Officer, Brent Saunders. Bertolini previously was Executive Vice President and Chief Financial Officer at Schering-Plough Corporation from 2003 until its merger with Merck & Co. in 2009. During his tenure, Bertolini worked as a business partner with the chief executive officer in all aspects of transforming the company's operations. Bertolini earned his bachelor's degree in economics at Rutgers, the State University of New Jersey, and is a Certified Public Accountant. He is a current board member of Actelion Pharmaceuticals and Charles River Labs, and a former board member of Genzyme Corporation.
Paragon Vision Sciences announced the introduction of NormalEyes 15.5, the only scleral lens design that employs a Dual Axis scleral landing zone. In addition this 15.5mm diameter design utilizes crossover technology combining the patented Proximity Control and Dual Axis technologies also found in Paragon CRT. Dual Axis Technology minimizes lens flexure and ensures rotational stability by providing appropriate sagittal depths in cross meridians. The Dual Axis feature results in predictable centration and provides enhanced comfort, according to the company. NormalEyes 15.5, the first Proximity Control Technology scleral lens, delivers precise corneal and limbal clearance and allows the eye care professional to control three independent zones. The Dual Axis landing zone allows near-equal circumferential scleral contact and simultaneous control of limbal clearance and edge lift. The patented convex to the eye posterior edge configuration results in predictable conjunctival compression without the possibility of corneal impingement. The lens is manufactured in Paragon HDS 100 material, laser marked with lens parameters, and is plasma treated. It can be prescribed on normal corneas, corneas with regular astigmatism, keratoconus, Post-LASIK, Post-RK, PKP, PMD and DALK. Two fitting sets can be purchased: the 72-Lens Full Fitting Set or a 21-Lens Starter Set. The lens is manufactured at Paragon's headquarters and distributed worldwide throughout their laboratory network. For an educational presentation, more information and to view the list distributing laboratories, visit their website.
The U.S. Food and Drug Administration is urging ophthalmologists to report occurrences of adverse patient reactions caused by decorative contact lenses to its MedWatch program. The FDA is emphasizing the need to report adverse reactions, especially if the lenses were purchased without a prescription, as the agency can only take action against illegal sellers when violations are reported. Consumers can report decorative lens-related problems directly to their local FDA Consumer Complaint Coordinator.
VISTAKON Division of Johnson & Johnson Vision Care, Inc., announced on February 28th that it will be discontinuing three of its older brands in 2013. ACUVUE® Brand Contact Lenses, the product that revolutionized the industry in 1987, will no longer be available in select base curves and parameters in the U.S. as of July 1, 2013. All 9.1 base curves and 8.4 and 8.8 base curves of parameters from -6.50 to -11.0 are being discontinued. Products with 8.4 and 8.8 base curves and parameters ranging from -0.50 to -6.00 will continue to be available. All parameters of ACUVUE® Brand Contact Lenses BIFOCAL and ACUVUE® 2® COLOURS® Brand Contact Lenses will be discontinued as of December 31, 2013. "Contact lens wearers continue to embrace innovative new materials, technologies, and designs that meet their vision, comfort, and lifestyle needs," says VISTAKON® president Dave Brown. "Providing patients the best vision correction product experience is a critical factor in helping eye care professionals serve their patients and grow their practice. Eye doctors can easily upgrade patients from these older lenses to more popular and innovative brands such as ACUVUE® OASYS® Brand Contact Lenses, 1-DAY ACUVUE® MOIST® Brand Contact Lenses, and 1-DAY ACUVUE® TruEye® Brand Contact Lenses. These brands are better poised to help make patients happy about the contact lenses they wear, and the doctor who fits them." ACUVUE® Brand Contact Lenses are indicated for vision correction. As with any contact lens, eye problems, including corneal ulcers, can develop. Some wearers may experience mild irritation, itching or discomfort. Lenses should not be prescribed if patients have any eye infection, or experience eye discomfort, excessive tearing, vision changes, redness or other eye problems. Consult the package insert for complete information. Complete information is also available from VISTAKON® Division of Johnson & Johnson Vision Care, Inc., by calling 1-800-843-2020 or by visiting their website.
MARK YOUR CALENDAR
The Third International Course of Orbitoplastic Surgery and New Trends in Ophthalmology will be held April 18 - 20 2013 in the Oscar Niemeyer Auditorium in Ravello, Italy. For more information visit www.strategieonweb.it or call 085-290-5407.
The Kiawah Eye CME Symposium will be held May 30 - June 1, 2013 on Kiawah Island, SC. This meeting is dedicated to providing a comprehensive meeting experience tailored to suit the needs of today's ophthalmologists. This interactive educational symposium will be offering up to 19.5 AMA PRA Category 1 Credits™ over a three-day program. For more information or to register, click here.
The European Contact Lens Society of Ophthalmologists (ECLSO) will be holding its annual meeting October 25- 27, 2013 in Munich, Germany. For more information visit www.eclso.eu.
The 2013 American Academy of Ophthalmology (AAO) Annual Meeting is scheduled for November 15-19, in New Orleans, LA. JCAHPO holds its annual ACE meeting in conjunction with the AAO.
The American Society of Cataract and Refractive Surgery Annual Meeting is scheduled for April 19-23, 2013 in San Francisco, CA. For more information visit www.ascrs.org.
CLAO "DID YOU KNOW?"
Did you know that next year (2014) will represent CLAO's golden anniversary (50 years since it was incorporated as a not-for-profit organization)?